IFNA1 and neoplasm: Preclinical models showed that inhibition of cycloxygenase-2 to mitigate the immunosuppressive tumor microenvironment by reducing PGE2 and IL-10 production58 or concomitant chemotherapy59 improved the efficacy of IFN gene therapy.